169 related articles for article (PubMed ID: 24615250)
1. Influence of SREBP-2 and SCAP gene polymorphisms on lipid-lowering response to atorvastatin in a cohort of Chilean subjects with Amerindian background.
Lagos J; Zambrano T; Rosales A; Salazar LA
Mol Diagn Ther; 2014 Aug; 18(4):435-43. PubMed ID: 24615250
[TBL] [Abstract][Full Text] [Related]
2. Atorvastatin effects on SREBF1a and SCAP gene expression in mononuclear cells and its relation with lowering-lipids response.
Arazi SS; Genvigir FD; Willrich MA; Hirata MH; Dorea EL; Bernik M; Hirata RD
Clin Chim Acta; 2008 Jul; 393(2):119-24. PubMed ID: 18435918
[TBL] [Abstract][Full Text] [Related]
3. APOE polymorphisms contribute to reduced atorvastatin response in Chilean Amerindian subjects.
Lagos J; Zambrano T; Rosales A; Salazar LA
Int J Mol Sci; 2015 Apr; 16(4):7890-9. PubMed ID: 25860945
[TBL] [Abstract][Full Text] [Related]
4. High baseline serum total and LDL cholesterol levels are associated with MDR1 haplotypes in Brazilian hypercholesterolemic individuals of European descent.
Rodrigues AC; Rebecchi IM; Bertolami MC; Faludi AA; Hirata MH; Hirata RD
Braz J Med Biol Res; 2005 Sep; 38(9):1389-97. PubMed ID: 16138223
[TBL] [Abstract][Full Text] [Related]
5. Influence of SCARB1 polymorphisms on serum lipids of hypercholesterolemic individuals treated with atorvastatin.
Cerda A; Genvigir FD; Arazi SS; Hirata MH; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
Clin Chim Acta; 2010 May; 411(9-10):631-7. PubMed ID: 20064494
[TBL] [Abstract][Full Text] [Related]
6. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population.
Giannakopoulou E; Ragia G; Kolovou V; Tavridou A; Tselepis AD; Elisaf M; Kolovou G; Manolopoulos VG
Mol Biol Rep; 2014 Jul; 41(7):4631-8. PubMed ID: 24668570
[TBL] [Abstract][Full Text] [Related]
7. Do MDR1 and SLCO1B1 polymorphisms influence the therapeutic response to atorvastatin? A study on a cohort of Egyptian patients with hypercholesterolemia.
Shabana MF; Mishriki AA; Issac MS; Bakhoum SW
Mol Diagn Ther; 2013 Oct; 17(5):299-309. PubMed ID: 23677857
[TBL] [Abstract][Full Text] [Related]
8. Identification of pharmacogenetic predictors of lipid-lowering response to atorvastatin in Chilean subjects with hypercholesterolemia.
Rosales A; Alvear M; Cuevas A; Saavedra N; Zambrano T; Salazar LA
Clin Chim Acta; 2012 Feb; 413(3-4):495-501. PubMed ID: 22120734
[TBL] [Abstract][Full Text] [Related]
9. Influence of PCSK9 polymorphisms on plasma lipids and response to atorvastatin treatment in Brazilian subjects.
Anderson JM; Cerda A; Hirata MH; Rodrigues AC; Dorea EL; Bernik MM; Bertolami MC; Faludi AA; Hirata RD
J Clin Lipidol; 2014; 8(3):256-64. PubMed ID: 24793346
[TBL] [Abstract][Full Text] [Related]
10. APOA1 polymorphisms are associated with variations in serum triglyceride concentrations in hypercholesterolemic individuals.
Sorkin SC; Forestiero FJ; Hirata MH; Guzmán EC; Cavalli SA; Bertolami MC; Salazar LA; Hirata RD
Clin Chem Lab Med; 2005; 43(12):1339-45. PubMed ID: 16309370
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics of OATP transporters reveals that SLCO1B1 c.388A>G variant is determinant of increased atorvastatin response.
Rodrigues AC; Perin PM; Purim SG; Silbiger VN; Genvigir FD; Willrich MA; Arazi SS; Luchessi AD; Hirata MH; Bernik MM; Dorea EL; Santos C; Faludi AA; Bertolami MC; Salas A; Freire A; Lareu MV; Phillips C; Porras-Hurtado L; Fondevila M; Carracedo A; Hirata RD
Int J Mol Sci; 2011; 12(9):5815-27. PubMed ID: 22016628
[TBL] [Abstract][Full Text] [Related]
12. CYP3A53A allele is associated with reduced lowering-lipid response to atorvastatin in individuals with hypercholesterolemia.
Willrich MA; Hirata MH; Genvigir FD; Arazi SS; Rebecchi IM; Rodrigues AC; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata RD
Clin Chim Acta; 2008 Dec; 398(1-2):15-20. PubMed ID: 18727922
[TBL] [Abstract][Full Text] [Related]
13. SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals.
Prado Y; Saavedra N; Zambrano T; Lagos J; Rosales A; Salazar LA
Int J Mol Sci; 2015 Aug; 16(9):20609-19. PubMed ID: 26334272
[TBL] [Abstract][Full Text] [Related]
14. The discrete and combined effect of SREBP-2 and SCAP isoforms in the control of plasma lipids among familial hypercholesterolaemia patients.
Durst R; Jansen A; Erez G; Bravdo R; Butbul E; Ben Avi L; Shpitzen S; Lotan C; Leitersdorf E; Defesche J; Friedlander Y; Meiner V; Miserez AR
Atherosclerosis; 2006 Dec; 189(2):443-50. PubMed ID: 16466730
[TBL] [Abstract][Full Text] [Related]
15. Apolipoprotein E mRNA expression in mononuclear cells from normolipidemic and hypercholesterolemic individuals treated with atorvastatin.
Cerda A; Genvigir FD; Willrich MA; Arazi SS; Bernik MM; Dorea EL; Bertolami MC; Faludi AA; Hirata MH; Hirata RD
Lipids Health Dis; 2011 Nov; 10():206. PubMed ID: 22074026
[TBL] [Abstract][Full Text] [Related]
16. Lack of association of the p450 oxidoreductase *28 single nucleotide polymorphism with the lipid-lowering effect of statins in hypercholesterolemic patients.
Ragia G; Kolovou V; Tavridou A; Elens L; Tselepis AD; Elisaf M; Van Schaik RH; Kolovou G; Manolopoulos VG
Mol Diagn Ther; 2014 Jun; 18(3):323-31. PubMed ID: 24430948
[TBL] [Abstract][Full Text] [Related]
17. Atorvastatin and hormone therapy effects on APOE mRNA expression in hypercholesterolemic postmenopausal women.
Issa MH; Cerda A; Genvigir FD; Cavalli SA; Bertolami MC; Faludi AA; Hirata MH; Hirata RD
J Steroid Biochem Mol Biol; 2012 Feb; 128(3-5):139-44. PubMed ID: 22094353
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of ezetimibe is not related to NPC1L1 gene polymorphisms in a pilot study of Chilean hypercholesterolemic subjects.
Zambrano T; Saavedra N; Lanas F; Caamaño J; Salazar LA
Mol Diagn Ther; 2015 Feb; 19(1):45-52. PubMed ID: 25589339
[TBL] [Abstract][Full Text] [Related]
19. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy.
Poduri A; Khullar M; Bahl A; Sehrawat BS; Sharma Y; Talwar KK
DNA Cell Biol; 2010 Oct; 29(10):629-37. PubMed ID: 20578904
[TBL] [Abstract][Full Text] [Related]
20. Antioxidant effect of atorvastatin is independent of PON1 gene T(-107)C, Q192R and L55M polymorphisms in hypercholesterolaemic patients.
Sardo MA; Campo S; Bonaiuto M; Bonaiuto A; Saitta C; Trimarchi G; Castaldo M; Bitto A; Cinquegrani M; Saitta A
Curr Med Res Opin; 2005 May; 21(5):777-84. PubMed ID: 15969877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
